-
Project P-K4
Click for more information -
VIDEOS: REPUBLICAN.TV
-
-
Global Perspectives on Good Governance
-
-
Comments
- china business|do business with chinese|china dictionary on China can’t lead global recovery
- Morning Sun on Religious sensitivities in Singapore and proper editorial judgement
- di on Religious sensitivities in Singapore and proper editorial judgement
- Oh Tham Eng on Religious sensitivities in Singapore and proper editorial judgement
- Fabian Chow on Religious sensitivities in Singapore and proper editorial judgement
- Daily SG: 28 Nov 2011 « The Singapore Daily on Reforming the Institution of Permanent Residency
- Daily SG: 28 Nov 2011 « The Singapore Daily on Religious sensitivities in Singapore and proper editorial judgement
- Davi Singh on Religious sensitivities in Singapore and proper editorial judgement
- NSP Malay Bureau's capitalizing? on Religious sensitivities in Singapore and proper editorial judgement
- Pin Liang Xin on Religious sensitivities in Singapore and proper editorial judgement
- Anon on 如果南洋大学延迟出世50年，今天的评语是不是有所不同
- cy on 如果南洋大学延迟出世50年，今天的评语是不是有所不同
- 可落意 on 如果南洋大学延迟出世50年，今天的评语是不是有所不同
- Daily SG: 25 Nov 2011 « The Singapore Daily on Self-designing your own course to future successes
- Michael on Apostasy in Malaysia: The hidden view
Tags
Creative Commons
Our articles and photographs are available to the public under Creative Commons. Click the Creative Commons logo for more information.
India Archive
-
Key political risks to watch in Asia in 2011
Posted on December 23, 2010 | 2 CommentsThe 2011 outlook is clouded by China's growing clout, the volatile situation on the Korean peninsula and corruption scandals in India. -
Asia’s Rise, ASEAN’s future
Posted on October 7, 2010 | 4 CommentsZainul Abidin Rasheed calls for caution. Emerging markets can't replace developed markets. The scale of the shift in capital towards Asia may overwhelm the existing policy tools. -
The role of WTO in the growing pharmaceutical divide
Posted on June 2, 2010 | 2 CommentsThe pharmaceutical divide in terms of drug access is perpetuated by the WTO TRIPS regime. The current TRIPS enforcement tilts in favour of the brand name drug companies holding the patent rights.
